A randomized, open-label study of the efficacy of trimetazidine in preventing acute myocardial injury in patients hospitalized for moderate to severe acute respiratory syndrome caused by SARS-CoV-2

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Risk factors: biomarkers Biomarkers ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

ESC 365 is supported by

ESC 365 is supported by